Ansbert Gadicke headshot

Ansbert Gadicke, M.D.

Investment Team

Investment and Operations Team

Cambridge Office

Dr. Ansbert Gadicke is Managing Director of MPM and its venture capital activities, as well as Managing Partner of BioImpact Capital, an affiliate manager of MPM and manager of the Oncology Impact Funds, private/public funds focused on oncology as well as new modalities.  He is the driving force at MPM behind building leading biopharmaceutical companies such as BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), and Pharmasset (acquired by Gilead Sciences) and, more recently, ElevateBio, Cullinan Oncology (NASDAQ: CGEM), Orna Therapeutics and AlloVir (NASDAQ: ALVR). MPM believes that these companies, in which Ansbert was the lead investor and served on the Boards of Directors, are some of the biggest successes in biotech – companies that ultimately result in helping thousands of patients live longer and vastly improved lives. For example, Sovaldi, developed by Pharmasset, was the first cure for Hepatitis C, the most successful product launch in the pharmaceutical industry and has today cured over 5 million patients of Hepatitis. Prior to founding MPM, Ansbert was at The Boston Consulting Group in their Boston office.

Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert and his co-founder Luke Evnin are recipients of the 2017 Global Oncology Visionary Award. He is a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.

Ansbert received an M.D. from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.